The potential role of the EGFR/ERBB2 heterodimer in breast cancer

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 6, 2007, Pages 607-616

  Cicenas, Jonas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Breast cancer; Epidermal growth factor receptor; ErbB2; Tyrosine kinase inhibitors

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BIBW 2992; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HETERODIMER; HKI 272; LAPATINIB; NVP AEE 788; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENICITY; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW;

EID: 34447266678     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.6.607     Document Type: Review

References (69)

1. HANKS SK, QUINN AM, HUNTER T: The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science (1988) 241(4861):42-52.
2. CARPENTER G, COHEN S: Epidermal growth factor. J. Biol. Chem. (1990) 265(14):7709-7712.
3. ULLRICH A, SCHLESSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61(2):203-212.
4. RIESE DJ, VAN RAAIJ TM, PLOWMAN GD et al.: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell Biol. (1995) 15(10):5770-5776.
5. TZAHAR E, WATERMAN H, CHEN X et al.: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. (1996) 16(10):5276-5287.
6. BAULIDA J, KRAUS MH, ALIMANDI M et al.: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. (1996) 271(9):5251-5257.
7. DOWNWARD J, WATERFIELD MD PARKER PJ: Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J. Biol. Chem. (1985) 260(27):14538-14546.
8. WILEY HS, HERBST JJ, WALSH BJ et al.: The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. (1991) 266(17):11083-11094.
9. WIKSTRAND CJ, HALE LP, BATRA SK et al.: Monoclonal antibodies against EGFRvII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. (1995) 55(14):3140-3148.
10. MOSCATELLO DK, HOLGADO-MADRUGA M, GODWIN AK et al.: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. (1995) 55(23):5536-5539.
11. SUGAWA N, EKSTRAND AJ, JAMES CD et al.: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA (1990) 87(21):8602-8606.
12. GILMORE T, DECLUE JE, MARTIN GS: Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitro. Cell (1985) 40(3):609-618.
13. KRIS RM, LAX I, GULLICK W et al.: Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein. Cell (1985) 40(3):619-625.
14. COUSSENS L, YANG-FENG TL, LIAO YC et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 230(4730):1132-1139.
15. KARUNAGARAN D, TZAHAR E, BEERLI RR et al.: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. (1996) 15(2):254-264.
16. STANCOVSKI I, PELES E, BEN LEVY R et al.: Signal transduction by die neu/erbB-2 receptor: a potential target for anti-tumor therapy. J. Steroid Biochem. Mol. Biol. (1992) 43(1-3):95-103.
17. BEN-LEVY R, PELES E, GOLDMAN-MICHAEL R et al.: An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. J. Biol. Chem. (1992) 267(24):17304-17313.
18. STERNBERG MJ, GULLICK WJ: Neu receptor dimerization. Nature (1989) 339(6226):587.
19. CAO H, DECKERS, STERN DF: TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Oncogene (1991) 6(5):705-711.
20. ECCLES SA, MODJTAHEDI H, BOX G et al.: Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis (1994-95) 14(1-6):337-348.
21. JARDINES L, WEISS M, FOWBLE B et al.: Neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology (1993) 61(5-6):268-282.
22. KRAUS MH, ISSING W, MIKI T et al.: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA (1989) 86(23):9193-9197.
23. PLOWMAN GD, CULOUSCOU JM, WHITNEY GS et al.: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA (1993) 90(5):1746-1750.
24. SOLTOFF SP, CARRAWAY KL, PRIGENT SA et al.: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell Biol. (1994) 14(6):3550-3558.
25. ZHANG K, SUN J, LIU N et al.: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. (1996) 271(7):3884-3890.
26. SRINIVASAN R, POULSOM R, HURST HC et al.: Expression of the c-ErbB4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. (1998) 185(3):236-245.
27. WIESMANN C, FUH G, CHRISTINGER HW et al.: Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Fit-1 receptor. Cell (1997) 91(5):695-704.
28. HUBBARD SR, WEI L, ELLIS L et al.: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature (1994) 372(6508):746-754.
29. PAWSON T, GISH GD: SH2 and SH3 domains: from structure to function. Cell (1992) 71(3):359-362.
30. SONGYANG Z, SHOELSON SE, CHAUDHURI M et al.: SH2 domains recognize specific phosphopeptide sequences. Cell (1993) 72(5):767-778.
31. MARGOLIS, B: The PTB Domain: the name doesn't say it all. Trends Endocrinol. Metab. (1999) 10(7):262-267.
32. KUNDRA V, ANAND-APTE B, FEIG LA et al.: The chemotactic response to PDGF-BB: evidence of a role for Ras. J. Cell Biol. (1995) 130(3):725-731.
33. SCHLESSINGER J, BAR-SAGI D: Activation of Ras and other signaling pathways by receptor tyrosine kinases. Cold Spring Harb. Symp. Quant. Biol. (1994) 59:173-179.
34. VALIUS M, KAZIAUSKAS A: Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptors mitogenic signal. Cell (1993) 73(2):321-334.
35. NOMURA M, HE Z, KOYAMA I et al.: Involvement of the Akr/mTOR pathway on EGF-induced cell transformation. Mol. Carcinog. (2003) 38(1):25-32.
36. PAWSON T: Protein modules and signalling networks. Nature (1995) 373(6515):573-580.
37. KARIN M, HUNTER T: Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr. Biol. (1995) 5(7):747-757.
38. MARSHALL CJ: MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. (1994) 4(1):82-89.
39. SEGER R, KREBS EG: The MAPK signaling cascade. Faseb J. (1995) 9(9):726-735.
40. RAMEH LE, CANTLEY LC: The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. (1999) 274(13):8347-8350.
41. CICENAS J, URBAN P, VUAROQUEAUX V et al.: Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res. (2005) 7(4):R394-R401.
42. HUNTER T: Signaling - 2000 and beyond. Cell (2000) 100(1):113-127.
43. BRANDT BH, ROETGER A, DITTMAR T et al.: c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. Faseb J. (1999) 13(14):1939-1949.
44. DITTMAR T, HUSEMANN A, SCHEWE Y et al.: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-ErbB2 receptor via EGFR. Faseb J. (2002) 16(13):1823-1825.
45. BROCKHOFF G, HEISS P, SCHLEGEL J et al.: Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry (2001) 44(4):338-348.
46. YOON SO, SHIN S, LIPSCOMB EA: A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res. (2000) 66(5):2732-2739.
47. DIERMEIER S, HORVATH G, KNUECHEL-CLARKE R et al.: Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER.2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp. Cell. Res. (2005) 304(2):604-619.
48. HAINSWORTH PJ, HENDERSON MA, STILLWELL RG et al.: Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur. J. Surg. Oncol. (1991) 17(1):9-15.
49. OSAKI A, TOI M, YAMADA H et al.: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am. J. Surg. (1992) 164(4):323-326.
50. HARLOZINSKA A, BAR JK, WENDERSKI R et al.: Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. In Vivo (1996) 10(2):217-222.
51. TORREGROSA D, BOLUFER P, LLUCH A et al.: Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin. Chim. Acta (1997) 262(1-2):99-119.
52. SHACKNEY SE, POLLICE AA, SMITH CA et al.: Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Clin. Cancer Res. (1998) 4(4):913-928.
53. KNOOP AS, BENTZEN SM, NIELSEN MM et al.: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. (2001) 19(14):3376-3384.
54. TSUTSUI S, OHNO S, MURAKAMI S et al.: Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery (2003) 133(2):219-221.
55. GRUPKA NL, LEAR-KAUL KC, KLEINSCHMIDT-DEMASTERS BK et al.: Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu. status. Arch. Pathol. Lab. Med. (2004) 128(9):974-979.
56. WISEMAN SM, MAKRETSOV N, NIELSEN TO et al.: Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer (2005) 103(9):1770-1777.
57. ANSQUERY, MANDELBROT L, LEHY T et al.: Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other ciinicopathological prognostic features. Anticancer Res. (2005) 25(6C):4535-4541.
58. PARK SS, KIM JE, KIM YA et al.: Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology (2005) 47(6):625-630.
59. OUYANG X, GULLIFORD T, ZHANG H et al.: Association of ErbB2 Serl 113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer. Mol. Cell Biochem. (2001) 218(1-2):47-54.
60. DIGIOVANNA MP, STERN DF, EDGERTON SM et al.: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. (2005) 23(6):1152-1160.
61. GSCHWANTLER-KAULICH D, HUDELIST G, KOESTLER WJ et al.: EGFR activity in HER-2 over-expressing metastatic breast cancer evidence for simultaneous phosphorylation of Her-2/neu and EGFR. Oncol. Rep. (2005) 14(2):305-311.
62. CICENAS J, URBAN P, KUNG W et al.: Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur. J. Cancer (2006) 42(5):636-645.
63. HUDELIST G, KOSTLER WJ, CZERWENKA K et al.: Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int. J. Cancer (2006) 118(5):1126-1234.
64. HOLBRO T, BEERLI RR, MAURER F et al.: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA (2003) 100(15):8933-8938.
65. CAPONIGRO F, MILANO A, OTTAIANO A et al.: Epidermal growth factor receptor as a major anticancer drug target. Expert Opin. Ther. Targets (2006) 10(6):877-888.
66. MOY B, GOSS PE: Lapatinib: current status and future directions in breast cancer. Oncologist(2006) 11(10):1047-1057.
67. STEEGHS N, NORTIER J, GELDERBLOM H: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. (2006) Nov 14 [Epub ahead of print].
68. HEYMACH JV, NILSSON M, BLUMENSCHEIN G et al.: Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res. (2006) 12(14 Pt 2):4441s-4445s.
69. YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. (2001) 2(2):127-137.